Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Merrimack Pharmaceuticals Inc    MACK

MERRIMACK PHARMACEUTICALS INC (MACK)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
5.52(c) 5.47(c) 5.67(c) 5.65(c) 5.57(c) Last
35 522 37 870 28 101 36 405 92 449 Volume
+2.03% -0.91% +3.66% -0.35% -1.42% Change
More quotes
Financials (USD)
Sales 2018 12,0 M
EBIT 2018 -58,7 M
Net income 2018 -59,7 M
Finance 2018 107 M
Yield 2018 -
Sales 2019 -
EBIT 2019 -78,5 M
Net income 2019 -81,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 -2,72x
Capi. / Sales2019 0
Capitalization 74,3 M
More Financials
Company
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer.Its pipeline includes MM-131, MM-141, and MM-310.The company... 
More about the company
Surperformance© ratings of Merrimack Pharmaceuticals
Trading Rating : Investor Rating : -
More Ratings
Latest news on MERRIMACK PHARMACEUTICALS
09/21MERRIMACK PHARMACEUTICALS : Receives $5 Million Milestone Payment from Shire
AQ
09/20MERRIMACK PHARMACEUTICALS : Receives $5 Million Milestone Payment from Shire
PR
09/13MERRIMACK PHARMACEUTICALS : Completes Enrollment in Randomized Phase 2 SHERLOC S..
AQ
09/10MERRIMACK PHARMACEUTICALS : Completes Enrollment in Randomized Phase 2 SHERLOC S..
AQ
09/07MERRIMACK PHARMACEUTICALS : Completes Enrollment in Randomized Phase 2 SHERLOC S..
AQ
09/06MERRIMACK PHARMACEUTICALS : Completes Enrollment in Randomized Phase 2 SHERLOC S..
PR
08/10Merrimack Reports Second Quarter 2018 Financial Results
AQ
08/07MERRIMACK PHARMACEUTICALS : Management's Discussion and Analysis of Financial Co..
AQ
08/07MERRIMACK PHARMACEUTICALS INC : Results of Operations and Financial Condition, F..
AQ
08/07MERRIMACK PHARMACEUTICALS INC : Merrimack Pharmaceuticals, Inc. to Host Earnings..
AC
More news
Sector news : Biotechnology & Medical Research - NEC
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/20Merrimack receives $5M milestone payment from Shire  
09/20$MACK Merrimack Receives $5 Million Milestone Payment from Shire From our Sto.. 
09/16Zacks: Brokerages Expect Merrimack Pharmaceuticals Inc $MACK Will Announce Ea.. 
09/14Want automatic email alerts for $TTEC $MACK $PSX $TLYS $YDLE? Subscribe to Ma.. 
09/10"Letting all the people know That I'm back to run the show..." Return of the ..
2
More tweets
Qtime:32
News from SeekingAlpha
09/20Merrimack receives $5M milestone payment from Shire 
09/07Merrimack Pharmaceuticals (MACK) Presents at Baird's Global Healthcare Confer.. 
09/06Merrimack Pharma completes enrollment in mid-stage study of MM-121 in certain.. 
08/07Merrimack Pharmaceuticals (MACK) CEO Richard Peters on Q2 2018 Results - Earn.. 
08/07Merrimack Pharmaceuticals misses by $0.05 
Chart MERRIMACK PHARMACEUTICALS INC
Duration : Period :
Merrimack Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERRIMACK PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 7,00 $
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Richard Peters President, Chief Executive Officer & Director
Gary L. Crocker Chairman
Jeffrey A. Munsie Secretary, Head-Operations & General Counsel
Jean M. Franchi CFO, Treasurer & Principal Accounting Officer
Sergio L. Santillana Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MERRIMACK PHARMACEUTICALS INC-45.66%75
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC30.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.69%14 156
SEATTLE GENETICS, INC.45.35%12 348